Wide Ranks

COEP

Coeptis Therapeutics Holdings,

0.1960

Top Statistics
Market Cap 8 M Forward PE -1.15 Revenue Growth 0.00 %
Current Ratio 0.55 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.5320 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 1 M Total Cash Per Share 0.0390 Total Debt 1 M
Total Debt To Equity Current Ratio 0.55 Book Value Per Share 0.0230
All Measures
Short Ratio 40.00 % Message Board Id finmb_593091629 Shares Short Prior Month 108289
Return On Equity -14.81 City Wexford Uuid 820436ab-e838-3404-bbe6-691814b0374c
Previous Close 0.1927 First Trade Date Epoch Utc 1 B Book Value 0.0230
Beta -0.9440 Total Debt 1 M Volume 57453
Price To Book 8.52 Fifty Two Week Low 0.1510 Total Cash Per Share 0.0390
Shares Short Previous Month Date 1 B Target Median Price 3.00 Max Age 86400
Sand P52 Week Change 0.3133 Target Mean Price 3.00 Net Income To Common -16142816
Short Percent Of Float 0.0044 Implied Shares Outstanding 41 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 148410 Average Volume10days 148410
Total Cash 1 M Next Fiscal Year End 1 B Held Percent Insiders 0.1853
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 0.1927 Target Low Price 3.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 0.1929 Open 0.1930 Free Cashflow -4444498
State PA Dividend Yield 0.00 % Return On Assets -1.87
Time Zone Short Name EST Trailing Eps -0.2800 Day Low 0.1930
Address1 105 Bradford Road Shares Outstanding 41 M Price Hint 4
Target High Price 3.00 Website https://coeptistx.com 52 Week Change -0.8325
Average Volume 255898 Forward Eps -0.1700 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 48.20 % Is_sp_500 False
Regular Market Day High 0.2072 Profit Margins 0.00 % Fifty Two Week High 1.28
Day High 0.2072 Shares Short 153027 Regular Market Open 0.1930
Industry Key biotechnology Earnings Growth 0.00 % Revenue Growth 0.00 %
Shares Percent Shares Out 0.0039 Operating Cashflow -6972284 Currency USD
Time Zone Full Name America/New_York Market Cap 8 M Is_nasdaq_100 False
Zip 15090 Quote Type EQUITY Industry Biotechnology
Long Name Coeptis Therapeutics Holdings, Inc. Regular Market Day Low 0.1930 Held Percent Institutions 0.0428
Current Price 0.1960 Address2 Suite 420 Enterprise To Ebitda -0.5320
Financial Currency USD Current Ratio 0.55 Industry Disp Biotechnology
Number Of Analyst Opinions 1 Country United States Float Shares 31 M
Two Hundred Day Average 0.2819 Enterprise Value 8 M Forward PE -1.15
Regular Market Volume 57453 Ebitda -16016634 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company.

It is developing cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes.

Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, natural killer cell therapy technology.

The company is also developing a multi-antigen CAR T technology licensed from the University of Pittsburgh, and the GEAR cell therapy and companion diagnostic platforms, which are developing with VyGen-Bio and medical researchers at the Karolinska Institute.

Its Product Pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.

The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases.

Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease.

The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.